MX2018007266A - Combinaciones para el tratamiento del cancer. - Google Patents
Combinaciones para el tratamiento del cancer.Info
- Publication number
- MX2018007266A MX2018007266A MX2018007266A MX2018007266A MX2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A MX 2018007266 A MX2018007266 A MX 2018007266A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- cancer
- treatment
- agent
- effective amount
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 101150111783 NTRK1 gene Proteins 0.000 abstract 1
- 101150117329 NTRK3 gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se describen combinaciones que comprenden una cantidad terapéuticamente eficaz de un primer agente y una cantidad terapéuticamente eficaz de un segundo agente, en donde el primer agente es un inhibidor de la actividad de ALK, ROS1, TrkA, TrkB o TrkC, o una combinación de estos, y los métodos para utilizar tales combinaciones en el tratamiento de pacientes que tienen cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269805P | 2015-12-18 | 2015-12-18 | |
US201662428498P | 2016-11-30 | 2016-11-30 | |
PCT/US2016/066919 WO2017106492A1 (en) | 2015-12-18 | 2016-12-15 | Combinations for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007266A true MX2018007266A (es) | 2018-11-09 |
Family
ID=59057572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007266A MX2018007266A (es) | 2015-12-18 | 2016-12-15 | Combinaciones para el tratamiento del cancer. |
Country Status (11)
Country | Link |
---|---|
US (2) | US10869864B2 (es) |
EP (1) | EP3389645A4 (es) |
JP (1) | JP7061068B2 (es) |
KR (1) | KR20180096621A (es) |
CN (1) | CN108697661A (es) |
AU (1) | AU2016370846B2 (es) |
BR (1) | BR112018012255A2 (es) |
CA (1) | CA3008663A1 (es) |
IL (1) | IL259996A (es) |
MX (1) | MX2018007266A (es) |
WO (1) | WO2017106492A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
US10085979B2 (en) | 2014-12-02 | 2018-10-02 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
KR20180096621A (ko) | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
JP7203083B2 (ja) * | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
US10180422B1 (en) * | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
JPWO2019049891A1 (ja) | 2017-09-06 | 2020-10-15 | 小野薬品工業株式会社 | Trk阻害剤とキナーゼ阻害剤の併用による癌治療方法 |
EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
WO2020035031A1 (en) * | 2018-08-16 | 2020-02-20 | Genentech, Inc. | Fused ring compounds |
JP2022504184A (ja) * | 2018-10-05 | 2022-01-13 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | ブドウ膜黒色腫の治療のための併用療法 |
CA3163095A1 (en) * | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
US11524006B2 (en) * | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041489A (ja) | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質k―252 |
WO1999043302A1 (en) | 1998-02-27 | 1999-09-02 | Watson Pharmaceuticals, Inc. | Stabilizing composition for pharmaceutical dosage forms |
OA11746A (en) * | 1999-01-13 | 2005-05-13 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors. |
JP2002275068A (ja) | 2001-03-16 | 2002-09-25 | Kyowa Hakko Kogyo Co Ltd | アポトーシス誘導剤 |
DE60215682T2 (de) | 2001-09-27 | 2007-09-06 | Smithkline Beecham Corp. | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ |
WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
AU2003251875A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
JP4648703B2 (ja) | 2002-09-05 | 2011-03-09 | アベンティス・ファーマ・ソシエテ・アノニム | 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物 |
WO2004062662A1 (fr) | 2002-12-12 | 2004-07-29 | Aventis Pharma S.A. | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
TW200423938A (en) | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
KR101106905B1 (ko) | 2003-02-26 | 2012-01-25 | 수젠, 인크. | 단백질 키나아제 억제제로서의 아미노헤테로아릴 화합물 |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
WO2005000786A1 (en) | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
ES2466818T3 (es) | 2003-09-26 | 2014-06-11 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
JP2007508801A (ja) | 2003-10-24 | 2007-04-12 | エスバテック・アーゲー | 受容体チロシンキナーゼ阻害剤の同定および/または確認のための方法 |
FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
US7605272B2 (en) | 2005-01-27 | 2009-10-20 | Kyowa Hakko Kirin Co., Ltd. | IGF-1R inhibitor |
WO2006111035A1 (en) | 2005-04-21 | 2006-10-26 | Oncalis Ag | Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle |
NZ564317A (en) | 2005-05-16 | 2011-01-28 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
BRPI0614809A2 (pt) | 2005-08-09 | 2011-04-12 | Johannes Gutenberg Universitaet Mainz | sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase |
CA2633584A1 (en) | 2005-12-20 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Glucokinase activators |
DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
WO2008005956A2 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
BRPI0722383A2 (pt) | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
EA200900783A1 (ru) | 2006-12-11 | 2009-12-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов киназы |
AU2007336335B8 (en) | 2006-12-20 | 2014-07-24 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
EP2173338A1 (en) * | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
HUE030929T2 (en) | 2007-07-20 | 2017-06-28 | Nerviano Medical Sciences Srl | Substituted imidazole derivatives having kinase activity |
CN109970759A (zh) | 2007-08-29 | 2019-07-05 | 梅特希尔基因公司 | 蛋白酪氨酸激酶活性的抑制剂 |
KR102037619B1 (ko) | 2008-10-22 | 2019-10-28 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
CN102924479A (zh) | 2011-08-09 | 2013-02-13 | 山东鲁北药业有限公司 | 一种星孢菌素类衍生物的半合成方法 |
JP2015508644A (ja) | 2012-02-08 | 2015-03-23 | インサイト ジェネティクス インコーポレイテッド | 癌の診断および治療のためのros1の融合体に関する方法および組成物 |
DK2822953T5 (en) | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
EP3333166B1 (en) | 2012-05-23 | 2019-11-06 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
KR20150100613A (ko) | 2012-09-28 | 2015-09-02 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 약제학적 제제 |
WO2014093750A1 (en) | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
ES2918375T3 (es) * | 2013-12-20 | 2022-07-15 | Biomed Valley Discoveries Inc | Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
KR102321883B1 (ko) | 2014-05-15 | 2021-11-03 | 어레이 바이오파마 인크. | TrkA 키나제 저해제로서의 1-((3S,4R)-4-(3-플루오로페닐)-1-(2-메톡시에틸)피롤리딘-3-일)-3-(4-메틸-3-(2-메틸피리미딘-5-일)-1-페닐-1H-피라졸-5-일)유레아 |
CA2951211A1 (en) | 2014-06-13 | 2015-12-17 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
CN203954606U (zh) | 2014-08-06 | 2014-11-26 | 朱红英 | 一种跳跳球 |
US10085979B2 (en) | 2014-12-02 | 2018-10-02 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
US20170356918A1 (en) | 2014-12-03 | 2017-12-14 | Ignyta, Inc. | Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer |
EP3303382A4 (en) | 2015-05-29 | 2018-12-19 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
US20180140604A1 (en) * | 2015-06-01 | 2018-05-24 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
TN2018000138A1 (en) * | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
KR20180096621A (ko) | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
JP7203083B2 (ja) | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
-
2016
- 2016-12-15 KR KR1020187016957A patent/KR20180096621A/ko not_active Application Discontinuation
- 2016-12-15 MX MX2018007266A patent/MX2018007266A/es unknown
- 2016-12-15 JP JP2018531120A patent/JP7061068B2/ja active Active
- 2016-12-15 WO PCT/US2016/066919 patent/WO2017106492A1/en active Application Filing
- 2016-12-15 CN CN201680078474.5A patent/CN108697661A/zh active Pending
- 2016-12-15 CA CA3008663A patent/CA3008663A1/en active Pending
- 2016-12-15 EP EP16876677.2A patent/EP3389645A4/en active Pending
- 2016-12-15 US US16/063,170 patent/US10869864B2/en active Active
- 2016-12-15 BR BR112018012255A patent/BR112018012255A2/pt not_active Application Discontinuation
- 2016-12-15 AU AU2016370846A patent/AU2016370846B2/en active Active
-
2018
- 2018-06-13 IL IL259996A patent/IL259996A/en unknown
-
2020
- 2020-12-09 US US17/116,929 patent/US20210113555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2019502683A (ja) | 2019-01-31 |
KR20180096621A (ko) | 2018-08-29 |
CA3008663A1 (en) | 2017-06-22 |
IL259996A (en) | 2018-07-31 |
US10869864B2 (en) | 2020-12-22 |
EP3389645A1 (en) | 2018-10-24 |
JP7061068B2 (ja) | 2022-04-27 |
CN108697661A (zh) | 2018-10-23 |
WO2017106492A1 (en) | 2017-06-22 |
US20190000840A1 (en) | 2019-01-03 |
BR112018012255A2 (pt) | 2018-12-04 |
AU2016370846B2 (en) | 2022-08-25 |
EP3389645A4 (en) | 2019-12-18 |
AU2016370846A1 (en) | 2018-07-05 |
US20210113555A1 (en) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018007266A (es) | Combinaciones para el tratamiento del cancer. | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
MX2017002489A (es) | Agentes terapeuticos humanos. | |
IN2014MU00303A (es) | ||
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
MX2017013047A (es) | Tratamiento de dolor. | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use |